Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FGFR4 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

FGFR4 amplification (2)

FGFR3 amplification + FGFR4 amplification + FLT4 amplification (1)

FGFR4 deletion (1)

FGFR4 amplification (2)

FGFR3 amplification + FGFR4 amplification + FLT4 amplification (1)

FGFR4 deletion (1)

›

FGFR4 mutation	Non Small Cell Lung Cancer	FGFR4 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
FGFR4 mutation	Melanoma	FGFR4 mutation	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
FGFR4 mutation	Melanoma	FGFR4 mutation	Melanoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
FGFR4 mutation	Melanoma	FGFR4 mutation	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
FGFR4 mutation	Solid Tumor	FGFR4 mutation	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR4 mutation	Gastric Cancer	FGFR4 mutation	Gastric Cancer	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D